© Copyright 2019 Doctors Without Borders (MSF) Southern Africa | MSF-SA Association | Southern Africa Medical Unit
Taxing the ill: How user fees are blocking Universal Health Coverage
Direct payments by patients at the point of health care delivery, commonly known as user fees, lead to low utilization or exclusion of health care services on offer, difficult assessment of health needs and epidemic risks, and impoverish entire households. Vulnerable groups are particularly affected.
Call for Proposal
The Fundraising department of Doctors Without Borders/ Medecins Sans Frontières (MSF) South Africa, wishes to replace the department’s software systems (CiviCRM) currently used to manage its private donor relationships and donation processing (CRM). MSF has selected Sales Force as the new software solution to support its current fundraising processes MSF South Africa is seeking a supplier to become a MSF partner for consultancy, process mapping, implementation, data modelling, data migration, training, development, upgrading, maintenance and technical support services.
Drug-Resistant Tuberculosis Treatment & Access to Delamanid in South Africa
Delamanid is one of the first new medicines developed for DR-TB treatment in 50 years. The standard treatment duration is for the first six months of DR-TB treatment. The WHO issued interim guidelines on DLM use to treat MDR-TB in November 2014 and on its use in treating children and adolescents in 2016. Delamanid is also included in the 19th WHO Model List of Essential medicines.
Threats to HIV treatment scale-up
ur toolkit for fighting HIV/AIDS has improved drastically from the start of the global HIV epidemic. With new diagnostic tools and more effective drug regimens, the curve of this epidemic can and will be bent. World leaders have made ambitious political commitments, by adopting the Sustainable Development Goals (SDGs) in 2015 “to end the AIDS epidemic by 2030.” However, to achieve any further progress, action is required now.
Waiting isn't an option: preventing and surviving advanced HIV
Data from MSF-supported hospitals presented at the IAS Conference on HIV Science in Paris today, highlights that in MSF-run and MSF-supported hospitals people arrive with such severe immune failure that overall mortality for patients presenting with AIDS is between 30-40%